Abstract: Novel polymer nanovectors or particles and use thereof as medication and/or diagnostic agents.

Abstract: A biodegradable iron oxide nanoparticle gel for hyperthermia treatment of cancer includes a polysaccharide-based carrier matrix and starch-coated iron oxide nanoparticles. The gel has sufficient deformability to integrate into a diffuse tumor site, adheres to tissue and has sufficient mechanical properties to remain in place during hyperthermia treatment. The gel releases iron oxide nanoparticles for uptake by cancerous cells at the tumor margin.

Abstract: A hair fixative composition includes a hair fixative polymer and a solvent system where the solvent system includes ethanol and another non-aqueous solvent in a weight ratio in a range of about 80:20 to about 20:80 of ethanol to the other non-aqueous solvent, and optionally a propellant.

Abstract: Topical alcohol-free thermo labile oily foam composition comprising (i) at least one active pharmaceutical ingredient or ectoparasitic active ingredient; (ii) at least about 20% w/w of at least one lipophilic component; (iii) at least about 10% w/w of at least one non-ionic surfactant; (iv) at least about 0.5% w/w of at least one fatty alcohol or fatty acid or ester thereof with melting point above 30° C.

Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.

Abstract: The following invention relates to a taste enhancer and a method of enhancing taste. The invention relates the use of a cooling enhancing composition which provides cooling enhancement when combined with other cooling compounds.

Abstract: The present invention relates to a p-menthane-3,8-diol isomer mixture 50% by mass or more of which is constituted of (1S)-isomers and a cooling sensation composition containing this mixture. The present invention also relates to a flavor and/or fragrance composition, food, beverage, cosmetic, daily use product, oral cavity composition, or pharmaceutical containing the p-menthane-3,8-diol isomer mixture in an amount of 0.0001 to 90% by mass.

Abstract: Substantially aqueous-free, enamel protectant and enamel repair toothpastes containing: stannous fluoride, calcium and a substantivity agent comprising: an emulsion of polydimethylsiloxane in a nonionic surfactant, wherein: (a) substantivity of said stannous fluoride and calcium into biofilm present on enamel is enhanced through calcium binding shifting from bidentate to monodentate in the presence of stannous fluoride; and (b) said toothpastes indicate substantially improved, enamel protectant factor (EPF) and enamel repair factor (ERF) values compared to fluoride brushing treatments with comparable or higher fluoride levels.

Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.

Abstract: A botanical tooth whitener composition comprises a quantity of camellia oil, a flavoring, and a thickening agent. The composition is comprised of natural substances and is generally free of chemical additives commonly found in related products. The composition may be used to reduce tooth discoloration or staining by brightening the teeth exposed thereto. A method of treating discolored or stained teeth comprises the steps of obtaining a botanical tooth whitener composition, dispensing a quantity thereof onto or into an applicator, and applying the composition to a tooth or teeth via the applicator. The applicator may be any of a spray bottle, brush pen, toothbrush, and dental tray.

Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Abstract: An oil-in-water emulsion includes, for 100 wt % thereof: a) 0.1 to 10 wt % of an emulsifying system including, for 100 wt % thereof: (i) 5 to 95 wt % of the mixture of the reaction products of a reducing sugar and 1,12-octadecanediol essentially consisting of hydroxyl-octadecyl polyglycosides of formula (I): HO—R—O-(G)n-H (I) and of polyglycosyl octadecyl polyglycosides of formula (II): H-(G)m-O—R—O-(G)p-H (II), where, in formulas (I) and (II), G is the remainder of the reducing sugar and R is the divalent radical octadecane-diyl-1,12, and where n, m and p, identical or different, each are, independently of each other, a decimal number between 1 and 5; (ii) 95 to 5 wt % of 1,12-octadecanediol; b) 0.01 to 5 wt % of at least one thickening and/or gelling agent; c) 10 to 50 wt % of an oil phase; and d) 89.89 to 35 wt % of an aqueous phase.

Abstract: Substantially anhydrous compositions including at least 10% by weight of a C2 or C3 mono-alcohol, a solid, organic UV-filter dissolved therein; and an oil portion including one or more oils, the oil portion having an interfacial tension with water of greater than 9 and less than 32.5, where the composition has a volume fraction of oil relative to oil plus C2 or C3 mono-alcohol that is about 0.44 or greater, and is substantially free of a mixture of a low-volatility, C2-C8 liquid silicone and a branched fatty acid ester of a polyprotic carboxylic acid in a ratio of from about 3:1 to 4.

Abstract: The present invention relates to a composition for topical application in the form of an oil-in-water (O/W) emulsion comprising in a physiologically acceptable medium at least a dibenzoylmethane derivative, an amino substituted hydroxybenzophenone derivative and a benzotriazol derivative.

Abstract: The present invention provides an external-use liquid skin-conditioning composition that not only reduces the sticky and friction sensations caused by the inclusion of tranexamic acid, but also has a rich body without feeling slimy and softens the skin after use. The composition comprises (A) 0.5 to 5 mass % of at least one hem selected from a group consisting of tranexarnic acid and derivatives thereof and (B) 0.005 to 1.5 mass % of carboxymethylcellulose, has a viscosity of no greater than 500 mPa·s at 30° C., and is transparent or semitransparent with an L value between 50 and 100 inclusive. Preferably the composition contains only carboxymethylcellulose as a thickener.

Abstract: Provided are a very safe skin whitening agent, melanin production inhibitor, and dopa oxidase activity inhibitor. Use of kitsunenomago or an organic solvent extract thereof to inhibit the dopa oxidase activity.

Abstract: The present disclosure relates generally to cosmetic powders having improved dispersibility, feel, and stability in which the powders are surface modified with at least one alginic acid, or salt form thereof. The powders may be used in cosmetic compositions such as a powder foundation skin toner, skin lotion, or body wash.

Abstract: The present invention relates to a composition for topical application comprising at least a benzotriazol derivative and a cosmetic solvent selected from the group consisting of benzoate solvents such as phenethyl benzoate, dimethyl capramide and diethylhexyl 2,6-naphthalate. Furthermore, the invention relates to the use of specific benzotriazol derivatives to mask the off-odor of cosmetic solvents such as particularly phenethyl benzoate, dimethyl capramide and diethylhexyl 2,6-naphthalate.

Abstract: The present invention refers to a complex for the improvement of distribution and retention of fragrances into keratinous matter comprising (a) C10-C18 alkyl pyrrolidone, (b) at least one polyol compound and (c) at least one fatty alcohol, as well as uses, products, and related methods. The complex of the present invention homogeneously distributes fragrance into the keratinous matter, achieving a better interaction between the fragrance and the keratinous substrate, and better and longer perception of it, ensuring greater durability of the fragrance.

Abstract: A method for forming a large particle complex comprising the steps of combining a hydrolyzed corn starch polymer, a starch/cellulose polymer, a hydrogenated phospholipid, and gum arabic in a cosmetically acceptable carrier to form a premix composition; heating said premix to about 85° C. for about 15 minutes; and cooling the composition to room temperature. The particle complex is useful as a component of a sprayable composition which provides volumizing, hair fixing, and conditioning as a leave-on treatment for human hair.

Abstract: Cosmetic composition comprising at least one particular amphoteric polymer and at least one particular conditioning agent The present invention relates to a cosmetic composition comprising: a)—one or more amphoteric polymers comprising a repetition of: (i) one or more units obtained from a monomer of (meth)acrylamide type, (ii) one or more units obtained from a monomer of (meth)acrylamidoalkyltrialkylammonium type, and (iii) one or more units obtained from an acidic monomer of (meth)acrylic acid type, the said amphoteric polymer(s) being present in the composition in an amount of between 0.

Abstract: Provided are microemulsions comprising: (a) at least one alkyl (oligo)glycoside, (b) at least one cosurfactant different from (a), (c) at least one non-water-soluble organic oil component, (d) at least one moisturizing agent, (e) and water. These microemulsions may be used for producing cleaning compositions and also cosmetic cleaning compositions, comprising: (A) any microemulsion provided herein, (B) one or more anionic surfactants, (C) one or more cationic polymers; (D) optionally further surfactants; (E) optionally cosmetic additives, and (F) water.

Abstract: An odor and ultra-violet light elimination formulation for application to hunting garments and equipment. The formulation has an ultra-violet light inhibitor which absorbs ultra-violet light emissions. The formulation also has a polymer providing a protective layer against odor causing molecules. And the formulation has a quaternary ammonium for eliminating odors and serving as a liquid chemical carrier for other formulation components.

Abstract: A deodorant comprises triethyl citrate, zinc glycinate, and water. The deodorant has a pH of 5.5 to 6.5.

Abstract: The present invention provides pharmaceutical compositions comprising an iodine-containing compound and a steroid, useful for treating a clinical symptom in a patient's airway (e.g., nose, lung, and sinus), as well as methods for using the same.

Abstract: Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof.

Abstract: Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.

Abstract: The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer.

Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.

Abstract: The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.

Abstract: The invention features methods of treating an immune disorder characterized by elevated Pin1 marker levels in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating immune disorders (e.g., immune disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with an anti-inflammatory, anti-viral, or anti-microbial compound.

Abstract: In one aspect, the invention provides compounds represented by Formula I, and pharmaceutically acceptable salts, esters, stereoisomers, tautomers, solvates, and combinations thereof, pharmaceutical compositions comprising these compounds and the use of these compounds for treating a viral infection in a subject.

Abstract: The present invention relates to fusion proteins in which a pharmaceutically active component is fused to an antibody mimetic. The invention specifically concerns fusion proteins comprising interferons or biologically active muteins thereof and modified hetero-dimeric ubiquitin proteins as specific targeting domain. The invention further relates to these fusion proteins for use in medicine, in particular for use in the treatment of cancer or infectious diseases. The invention is further directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with such fusion proteins, and in combination with cancer therapeutic agents. Moreover, the invention relates to a method for the generation of said fusion proteins.

Abstract: The present invention relates a novel composition for preventing or treating hepatitis C virus, regulating the phosphorylation of a replicase. More specifically, it is possible to prevent or treat hepatitis C using a novel PRK2 inhibitor discovered through structure modeling, and to prevent or treat hepatitis C, particularly, interferon-insensitive hepatitis C through coadministration of an Hsp90 inhibitor.

Abstract: A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency.

Abstract: Porous chitosan scaffold having high mechanical strength, methods for making the porous chitosan scaffold, and method for using the porous chitosan scaffold.

Abstract: Provided are methods for preparing gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth scaffolds. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.

Abstract: Methods for inducing cardiomyocyte proliferation, e.g., in vivo, by administering a composition comprising miRNA17-92 cluster oligonucleotides, e.g., miR-19a oligonucleotides, miR-19b oligonucleotides, or both miR-19a and miR-19b oligonucleotides.

Abstract: A method for treating obesity, insulin sensitivity, and related conditions involves administering to the subject a bacterium for overexpressing a N-acyl-phosphatidylethanolamine (NAPE) and/or a N-acylethanolamine (NAE). A composition includes a bacterium for overexpressing a N-acyl-phosphatidylethanolamine (NAPE) and/or a N-acylethanolamine (NAE); and an ingestible vehicle in which the bacterium is provided.

Abstract: Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.

Abstract: Animal feed conversion ratio can be increased and blood glucose levels can be decreased by feeding an efficacious amount of dispersible amorphous poly(3-hydroxybutyrate/3-hydroxyvalerate).

Abstract: The present invention relates to novel bacteriophages and bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them, all of them belonging to the Caudovirales order. The novel bacteriophages and the bacteriophage cocktails containing the novel bacteriophages and or parts and/or products of them are Salmonella specific bacteriophages and have lytic activity against Salmonella.

Abstract: Methods are described for the isolation and selection of a heterogeneous bone marrow cell population, called NCS-01, that is effective at treating neurodegeneration. For example, NCS-01 cells are shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrate that selected NCS-01 cell populations treat neurodegeneration in a standard rat middle cerebral artery occlusion (MCAO) animal model under conditions of transient or permanent total arterial occlusion. These studies also disclose that when the neurodegeneration is caused by ischemic stroke, combining the administration of a selected NCS-01 cell population with thrombolytic agents and/or mechanical methods of clot removal leads to a decrease in the volume of infarction caused by acute onset neurodegeneration. The disclosed cell therapy promises to make a significant clinical impact on patient survival after stroke.

Abstract: Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof.

Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.

Abstract: Methods of regenerating tissue using progenitor cells in combination with primary cells from a target tissue are disclosed. In particular, progenitor cells catalyze proliferation and tissue production by primary cells allowing the use of fewer primary cells from a target tissue for effective tissue regeneration. Cell-based therapies combining progenitor cells and primary cells can be used for repair and regeneration of damaged tissue and organs for treating bodily injuries and degenerative diseases. For example, adipose-derived stem cells and neonatal articular chondrocytes, co-encapsulated in mixed or bilayered cultures in a hydrogel comprising chondroitin sulfate methacrylate and poly(ethylene)glycol diacrylate, generated cartilage that could be used for treatment of traumatic injuries or diseases involving cartilage degeneration.

Abstract: A nanocomposite hydrogel formed from free radical dissociation of an initiator and polymerisation of a water soluble monomer. The resulting hydrogel finds particular application within the medical field for both soft and hard tissue repair in human and animals. The hydrogel is particularly advantageous for spinal disc repair.

Abstract: Embodiments of the invention are directed to compositions comprising a peptide sequence, or a nucleic acid encoding the same, wherein the peptide sequence includes a receptor-binding region of apolipoprotein E (apoE), or a sequence variant or fragment thereof, for directing delivery of a given protein or therapeutic across the blood brain barrier. Embodiments of the invention are also directed to methods of using the compositions for treating or preventing a neurological disorder, disease, or symptom in a subject in need thereof.